Risk of endometrial cancer after RRSO in BRCA 1/2 carriers: a multicentre cohort study

被引：0

作者：

Pla-Juher, Helena ^{[1
,2
,4
]}

Pardo, Marta ^{[2
]}

Izquierdo, Angel J. ^{[2
,3
,4
]}

Darder, Esther ^{[3
,4
]}

Carbo, Anna ^{[1
,2
,4
]}

Munte, Elisabet ^{[5
]}

Torres-Esquius, Sara ^{[6
]}

Balmana, Judith ^{[6
]}

Lazaro, Concepcion ^{[5
,7
]}

Brunet, Joan M. ^{[1
,2
,3
,4
]}

Barretina-Ginesta, Maria-Pilar ^{[1
,2
,4
]}

机构：

[1] Hosp Univ Dr Josep Trueta, Catalan Inst Oncol, Med Oncol, Avinguda Franca S-N, Girona 17707, Spain

[2] Inst Invest Biomed Girona IDIBGI, Precis Oncol Grp OncoGIR Pro, Girona, Spain

[3] IDIBGI, Catalan Inst Oncol, Hereditary Canc Program, Girona, Spain

[4] Dept Epidemiol & Canc Register, Girona, Spain

[5] IDIBELL, Catalan Inst Oncol, Hereditary Canc Program, Barcelona, Spain

[6] Vall dHebron Hosp, Dept Med Oncol, Barcelona, Spain

[7] Inst Salud Carlos III, Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain

来源：

CLINICAL & TRANSLATIONAL ONCOLOGY | 2024年 / 26卷 / 04期

关键词：

Endometrial cancer; Breast cancer; Risk-reducing salpingo-oophorectomy; BRCA; Mutation; Hysterectomy; Tamoxifen; Carcinosarcoma; Serous carcinoma; Endometrioid carcinoma; REDUCING SALPINGO-OOPHORECTOMY; UTERINE SEROUS CARCINOMA; BRCA2; MUTATIONS; BREAST-CANCER; WOMEN; HYSTERECTOMY; METAANALYSIS; SURGERY; TIME;

D O I：

10.1007/s12094-023-03312-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objective To know the risk of endometrial cancer (EC) in a population of women with BRCA 1/2 pathogenic or likely pathogenic variants after risk-reducing salpingo-oophorectomy (RRSO).Methods The study cohort included data from 857 women with BRCA mutations who underwent RRSO visited four hospitals in Catalonia, Spain, from January 1, 1999 to April 30, 2019. Standardized incidence ratio (SIR) of EC was calculated in these patients using data from a regional population-based cancer registry.Results After RRSO, eight cases of EC were identified. Four in BRCA 1 carriers and four in BRCA2 carriers. The expected number of cases of EC was 3.67 cases, with a SIR of 2.18 and a 95% CI (0.93-3.95).Conclusions In our cohort, the risk of EC in BRCA1/2 carriers after RRSO is not greater than expected. Hysterectomy is not routinely recommended for these patients.

引用

页码：1033 / 1037

页数：5

共 50 条

[41] Screening for ovarian cancer in BRCA1/BRCA2 mutations carriers
Synowiec, Agnieszka
Wcislo, Gabriel
Bodnar, Lubomir
Gasowska-Bodnar, Agnieszka
Szczylik, Cezary
GINEKOLOGIA POLSKA, 2014, 85 (05) : 377 - 381
[42] Pregnancy after breast cancer in BRCA1/2 mutation carriers
Maksimenko, Jelena
Irmejs, Arvids
Gardovskis, Janis
HEREDITARY CANCER IN CLINICAL PRACTICE, 2022, 20 (01)
[43] Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers
Oden, Lovisa
Akbari, Mohammad
Zaman, Tasnim
Singer, Christian F.
Sun, Ping
Narod, Steven A.
Salmena, Leonardo
Kotsopoulos, Joanne
ONCOTARGET, 2016, 7 (52) : 86687 - 86694
[44] Prospective evaluation of body size and breast cancer risk among BRCA1 and BRCA2 mutation carriers
Kim, Shana J.
Huzarski, Tomasz
Gronwald, Jacek
Singer, Christian F.
Moller, Pal
Lynch, Henry T.
Armel, Susan
Karlan, Beth Y.
Foulkes, William D.
Neuhausen, Susan L.
Senter, Leigha
Eisen, Andrea
Eng, Charis
Panchal, Seema
Pal, Tuya
Olopade, Olufunmilayo
Zakalik, Dana
Lubinski, Jan
Narod, Steven A.
Kotsopoulos, Joanne
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2018, 47 (03) : 987 - 997
[45] Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis
Heemskerk-Gerritsen, B. A. M.
Menke-Pluijmers, M. B. E.
Jager, A.
Tilanus-Linthorst, M. M. A.
Koppert, L. B.
Obdeijn, I. M. A.
van Deurzen, C. H. M.
Collee, J. M.
Seynaeve, C.
Hooning, M. J.
ANNALS OF ONCOLOGY, 2013, 24 (08) : 2029 - 2035
[46] Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits
Schrijver, Lieske H.
Mooij, Thea M.
Pijpe, Anouk
Sonke, Gabe S.
Mourits, Marian J. E.
Andrieu, Nadine
Antoniou, Antonis C.
Easton, Douglas F.
Engel, Christoph
Goldgar, David
John, Esther M.
Kast, Karin
Milne, Roger L.
Olsson, Hakan
Phillips, Kelly-Anne
Terry, Mary Beth
Hopper, John L.
van Leeuwen, Flora E.
Rookus, Matti A.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2022, 114 (04): : 540 - 552
[47] Breast Cancer Risk and Breast-Cancer-Specific Mortality following Risk-Reducing Salpingo-Oophorectomy in BRCA Carriers: A Systematic Review and Meta-Analysis
Gaba, Faiza
Blyuss, Oleg
Tan, Alex
Munblit, Daniel
Oxley, Samuel
Khan, Khalid
Legood, Rosa
Manchanda, Ranjit
CANCERS, 2023, 15 (05)
[48] Trends and timing of risk-reducing mastectomy uptake in unaffected BRCA1 and BRCA2 carriers in Slovenia
Lozar, Taja
Zgajnar, Janez
Perhavec, Andraz
Blatnik, Ana
Novakovic, Srdjan
Krajc, Mateja
EJSO, 2021, 47 (08): : 1900 - 1906
[49] Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers
T C van Sprundel
M K Schmidt
M A Rookus
R Brohet
C J van Asperen
E J Th Rutgers
L J van‘t Veer
R A E M Tollenaar
British Journal of Cancer, 2005, 93 : 287 - 292
[50] Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers
van Sprundel, TC
Schmidt, MK
Rookus, MA
Brohet, R
van Asperen, CJ
Rutgers, EJT
van't Veer, L
Tollenaar, RAEM
BRITISH JOURNAL OF CANCER, 2005, 93 (03) : 287 - 292

← 1 2 3 4 5 →